Annexon Announces Topline Data From RWE Study Of ANX005 For Guillain-Barré Syndrome, Stock Up

(RTTNews) - Annexon, Inc. (ANNX) on Monday announced positive topline results from a real-world evidence study supporting ANX005 as a potential treatment for Guillain-Barr Syndrome, a rapid-onset and acute neuromuscular disease.

The company found that patients treated with ANX005 showed faster and greater improvement in muscle strength and disability compared to patients in the matched International GBS Outcomes Study cohort treated with IVIg or PE.

Also, ANX005-treated patients were observed to spend less time on ventilation and less time in the intensive care unit, and only a few of these patients required mechanical ventilation.

Following the promising results, the company plans to submit a U.S. Biologics License application in the first half of 2025.

Currently, Annexon's stock is climbing 11.15 percent, to $4.94 percent on the Nasdaq.